Key facts
- It has raised $22.9M; the latest was Later Stage VC ($18.9M) in Nov 2025.
- Notable investors include Hostplus Superannuation Fund, Brandon Biocatalyst, IP Group, IP Group Australia, Jumar Bioincubator — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for RAGE Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for RAGE Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RAGE Biotech
Developer of novel therapies designed for the treatment of respiratory diseases. The company engages in the modulation of receptors for advanced glycation end-products that are crucial to targeting chronic inflammation, which is a multi-ligand, transmembrane receptor expressed in the lung, providing patients with treatment options for difficult-to-treat inflammatory conditions such as severe asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD).
- Sector
- Healthcare
- HQ
- Melbourne, Australia
- Founded
- 2020
- Employees
- 8
- Website
- ragebio.com/
- Ownership
- Privately Held (backing)
RAGE Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RAGE Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RAGE Biotech in its N-PORT filings yet. We sweep new filings monthly.